Preclinical Services for HIV Therapeutics

The National Institutes of Health awarded a competitive multiple-award, Indefinite Delivery/Indefinite Quantity (IDIQ) contract to support Preclinical Services for HIV Therapeutics under solicitation number 75N93019R00021. The contract features a seven-year ordering period effective from October 15, 2020, through October 14, 2027. Work performed under this vehicle is classified under NAICS 541715 for Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC AJ12 for General Science and Technology R&D Services; General Science and Technology; Applied Research.

The primary place of performance is Iowa City, Iowa. Task orders issued against this contract are anticipated to be cost-reimbursement, term, or completion types, though fixed-price orders may be utilized when appropriate. The government determined that cost-reimbursement structures are necessary due to the dynamic nature of the scientific requirements and the absence of precise specifications, which make accurate cost estimation difficult. These flexible arrangements allow the agency to shift responsively with evolving research needs while avoiding the undue risk associated with fixed-price environments for result-driven science.

The awarded contractor is eligible to compete for task orders specifically within Task Area E. This award notice follows the initial solicitation posted on the federal contracting portal. Robert Corno serves as the point of contact for this requirement, which contains no associated attachments in the final award announcement published on October 20, 2020.